AstraZeneca

At AstraZeneca, we are committed to driving progress through innovation and collaboration – across the UK and within the thriving Cambridge region. We're proud to share that our UK Chair, Shaun Grady, will be a member of a newly launched Advisory Council assembled by Innovate Cambridge, bringing together world-leading expertise to advance Cambridge as a globally leading, inclusive innovation ecosystem. Announced yesterday by Lord Vallance, Minister of State for Science, Research and Innovation and Oxford-Cambridge Innovation Champion, the Advisory Council will guide Cambridge’s role in shaping frontier technologies such as AI, life sciences, and quantum computing and catalyse its potential to deliver substantial societal, environmental and economic benefits regionally and nationally. As we push the boundaries of science, advance cutting-edge technology, and support sustainable growth across Cambridge, we are honoured to work hand-in-hand with the community and forward-thinking leaders to champion Cambridge innovation for societal good.

Today we announced plans to establish a new global strategic R&D centre in Beijing to advance our global efforts to bring innovative medicines to patients worldwide. This investment reflects the rapid advancement of Beijing's world-class life sciences ecosystem, the extensive opportunities for collaboration, access to talent, and our continued commitment to China. Beijing will become our second strategic R&D centre in China, alongside Shanghai, and our sixth worldwide, with two centres in the US and two in Europe. #WhatScienceCanDo #AstraZenecaBusinessNews

Approximately 15-20% of the world’s population is neurodivergent, which recognizes alternative thinking styles such as Dyslexia, DCD (Dyspraxia), Dyscalculia, Autism, and ADHD. Our TH!NK Neurodiversity Employee Resource Group (ERG) fosters global conversations to create an inclusive and equitable environment for all. With the right tools and resources, we can support our neurodivergent community to thrive through a culture of lifelong learning and development. #WhatScienceCanDo #NeurodiversityCelebrationWeek

Our Executive Vice President of Operations and IT and Chief Sustainability Officer, Pam Cheng, spoke to The Times about our Young Health Programme’s partnership with UNICEF. We’re empowering young people to advocate for the prevention of non-communicable diseases and tackle climate-related health challenges. As Pam says: “We encourage organisations to drive collective action to advance health equity, address the impact of climate change on public health, and build more resilient health systems - for the benefit of people, society and the planet.” Learn more: https://learn.az/60470UAmW #YoungHealthProgramme

For #Investors and #Media Today we announced an agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies. We believe EsoBiotec’s world-leading in vivo cell therapy platform has the potential to transform cell therapy, increasing the number of patients that may be able to access and benefit from these innovative treatments. Traditional cell therapies require cells be removed from a patient, genetically modified outside of the body, and then readministered to the patient as a medicine after immune cell depletion, a process that typically takes weeks. In vivo cell therapy enables administration of cell therapies in minutes, through a simple IV injection and without the need for immune cell depletion. By engineering immune cells directly within the patient’s body, the platform offers a promising approach to streamline processes, reducing complexities and manufacturing timelines, while increasing patient access. #AstraZenecaBusinessNews

Every patient deserves a timely diagnosis. Transthyretin-mediated amyloidosis (ATTR) is a complex, often undetected condition that can be life threatening if left untreated. At AstraZeneca, we’re advancing cutting edge science to improve early detection, raise awareness and drive meaningful change for patients living with ATTR. Discover how we’re making a difference: https://learn.az/60470BoUc

Our CEO Pascal Soriot joined His Majesty King Charles III, global CEOs and world leaders at the Sustainable Markets Initiative 2025 Terra Carta Roundtables & Exhibition. Investing in a sustainable transition is vital to unlock long-term economic growth, drive resilience across markets and improve the health of people, society and the planet. Learn about the collective impact of the SMI Health Systems Task Force, which Pascal chairs, here: https://learn.az/60410RUXD #SMITerraCarta

Chronic kidney disease (CKD) silently affects millions worldwide, often going undiagnosed until it’s too late. Targeted screening policies can change that. As we mark 20 years of #WorldKidneyDay, the need for action has never been more urgent, as the clinical, socioeconomic, and environmental burden of CKD continues to rise. It’s time to act now. Learn more and help shape the future of kidney health: https://learn.az/6041LjhNb #KidneyHealthMatters #ForKidneyHealth

We follow the science to unlock the future of novel therapies that target the root cause of disease. Genomics has helped us uncover much about human health, but it only tells part of the story. Multiomics is unlocking deeper insights, transforming how we detect, understand and treat chronic diseases. Discover how this approach is shaping the future of medicine: https://learn.az/60440GPGq #WhatScienceCanDo

Our CFO, Aradhana Sarin, recently hosted research psychologist and award-winning professor, Alison Fragale, on her podcast “In Conversation with…”. This must-watch episode offers science-based strategies for women to confidently advocate for themselves. Discover how you can use these universal tools to negotiate, influence, and lead effectively: https://learn.az/604201omE #WhatScienceCanDo #LeadershipDevelopment